Clinical Journal of Gastroenterology

, Volume 3, Issue 6, pp 307–317

Gastrointestinal bleeding during anti-angiogenic peptide vaccination in combination with gemcitabine for advanced pancreatic cancer

  • Hitomi Nagayama
  • Kazufumi Matsumoto
  • Naoyuki Isoo
  • Hideki Ohno
  • Naoyuki Takahashi
  • Takashi Nakaoka
  • Masaru Shinozaki
  • Makoto Watanabe
  • Yusuke Inoue
  • Fumitaka Nagamura
  • Naoki Oyaizu
  • Naohide Yamashita
Case Report

DOI: 10.1007/s12328-010-0178-5

Cite this article as:
Nagayama, H., Matsumoto, K., Isoo, N. et al. Clin J Gastroenterol (2010) 3: 307. doi:10.1007/s12328-010-0178-5

Abstract

Most pancreatic cancer patients are diagnosed at the advanced stages, and no therapy is superior to gemcitabine alone. To confirm the feasibility and efficacy of a novel clinical intervention using tumor vessel-specific anti-angiogenic peptide vaccination, we conducted a clinical phase I/II trial using HLA-A*2402/A*0201-restricted vascular endothelial growth factor receptor type 1 (VEGFR1)-derived peptide vaccination in combination with gemcitabine for advanced pancreatic cancer (http://www.clinical-trials.gov; NCT00683358 and NCT00683085). Four of the enrolled patients (n = 2 for HLA-A*2402 and n = 2 for HLA-A*0201 protocol, respectively), defined as having progressive disease according to the Response Evaluation Criteria in Solid Tumors version 1.0 (RECIST v.1.0), failed to respond to the therapy. Another two patients enrolled in HLA-A*2402 protocol dropped out of the study due to rapid disease progression. Grade 2–3 hematologic toxicities were observed in all cases, but the treatment was well tolerated with minimal systemic adverse events. One case in HLA-A*2402 protocol and another case in HLA-A*0201 protocol suffered complicated gastrointestinal (GI) bleeding during vaccination. The causal relationship between GI bleeding and VEGFR1-peptide vaccination is unclear according to the pathologic examination. These studies terminated prematurely because of the advanced stage of the disease in the enrolled patients on entry to the study. Despite GI bleeding, peptide vaccination provides a feasible treatment option for many advanced pancreatic cancer patients.

Keywords

Pancreatic cancer Peptide vaccination VEGFR1 Gemcitabine GI bleeding 

Copyright information

© Springer 2010

Authors and Affiliations

  • Hitomi Nagayama
    • 1
  • Kazufumi Matsumoto
    • 2
  • Naoyuki Isoo
    • 1
  • Hideki Ohno
    • 1
  • Naoyuki Takahashi
    • 1
  • Takashi Nakaoka
    • 1
  • Masaru Shinozaki
    • 3
  • Makoto Watanabe
    • 4
  • Yusuke Inoue
    • 4
  • Fumitaka Nagamura
    • 2
  • Naoki Oyaizu
    • 5
  • Naohide Yamashita
    • 1
  1. 1.Division of Advanced Medical Science, Research Hospital, The Institute of Medical ScienceThe University of TokyoTokyoJapan
  2. 2.Department of Clinical Trial Safety Management, The Institute of Medical ScienceThe University of TokyoTokyoJapan
  3. 3.Department of Surgery, The Institute of Medical ScienceThe University of TokyoTokyoJapan
  4. 4.Division of Radiology, The Institute of Medical ScienceThe University of TokyoTokyoJapan
  5. 5.Division of Pathology, Research Hospital, The Institute of Medical ScienceThe University of TokyoTokyoJapan

Personalised recommendations